AR086086A1 - Derivados glucosidos y usos de los mismos - Google Patents
Derivados glucosidos y usos de los mismosInfo
- Publication number
- AR086086A1 AR086086A1 ARP120101273A ARP120101273A AR086086A1 AR 086086 A1 AR086086 A1 AR 086086A1 AR P120101273 A ARP120101273 A AR P120101273A AR P120101273 A ARP120101273 A AR P120101273A AR 086086 A1 AR086086 A1 AR 086086A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- group
- membered heteroaryl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.Reivindicación 1: Un compuesto representado por la fórmula estructural (1) o una sal farmacéuticamente aceptable del mismo, en donde: A se selecciona entre los restos del grupo de fórmulas (2); V es hidrógeno, halo u OR1b-; R1, R1a y R1b se seleccionan independientemente del grupo constituido por hidrógeno, alquilo C1-6, aril C6-10-alquilo C1-4, -C(O)-arilo C6-10 y -C(O)-alquilo C1-6; R2 y R2a, en cada caso, se seleccionan independientemente entre el grupo formado por halo, hidroxilo, alquilo C1-6, y alcoxilo C1-6; R3 es halo, hidroxilo, alquilo C1-6, haloalquilo C1-6-, cicloalquilo C3-10-, alcoxilo C1-6, o halo-alcoxilo C1-3-; R4 se selecciona del grupo de fórmulas (3); R5 es una cadena lateral de aminoácidos; R6 es un alquilo C1-6, cicloalquilo C3-10, cicloalquil C3-10-alquilo C1-4, heterocicloalquilo de 3- a 10- miembros, (heterocicloalquilo de 3- a 10- miembros)-alquilo C1-4, arilo C6-10, arilo C6-10-alquilo C1-4, heteroarilo de 5- a 10- miembros, o (heteroarilo de 5- a 10- miembros)-alquilo C1-4; R7, para cada ocurrencia, es independientemente hidrógeno, alquilo C1-6, cicloalquilo C3-10, cicloalquil C3-10-alquilo C1-4, heterocicloalquilo de 3- a 10- miembros, (heterocicloalquilo de 3- a 10- miembros)-alquilo C1-4, arilo C6-10, aril C6-10-alquilo C1-4, heteroarilo de 5- a 10- miembros, o (heteroarilo de 5- a 10- miembros)-alquilo C1-4; n es 0, 1, 2, ó 3, y q es 0, 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475476P | 2011-04-14 | 2011-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086086A1 true AR086086A1 (es) | 2013-11-20 |
Family
ID=46028035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101273A AR086086A1 (es) | 2011-04-14 | 2012-04-13 | Derivados glucosidos y usos de los mismos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8614195B2 (es) |
| EP (1) | EP2697217B1 (es) |
| JP (1) | JP5908973B2 (es) |
| KR (1) | KR20140027250A (es) |
| CN (1) | CN103748090B (es) |
| AP (1) | AP2013007179A0 (es) |
| AR (1) | AR086086A1 (es) |
| AU (1) | AU2012241427B2 (es) |
| BR (1) | BR112013026257A2 (es) |
| CA (1) | CA2832958A1 (es) |
| CL (1) | CL2013002973A1 (es) |
| CO (1) | CO6781541A2 (es) |
| CR (1) | CR20130530A (es) |
| CU (1) | CU20130139A7 (es) |
| EA (1) | EA201391525A1 (es) |
| ES (1) | ES2621007T3 (es) |
| IL (1) | IL228771A0 (es) |
| MA (1) | MA35032B1 (es) |
| MX (1) | MX2013011927A (es) |
| PE (1) | PE20141039A1 (es) |
| PH (1) | PH12013502140A1 (es) |
| SG (1) | SG194463A1 (es) |
| TN (1) | TN2013000413A1 (es) |
| TW (1) | TW201245219A (es) |
| UY (1) | UY34018A (es) |
| WO (1) | WO2012140597A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903445T4 (tr) | 2011-06-01 | 2019-03-21 | Green Cross Corp | Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇ |
| FI2981269T3 (fi) | 2013-04-04 | 2023-09-27 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimillä |
| ES2828548T3 (es) * | 2013-09-09 | 2021-05-26 | Youngene Therapeutics Co Ltd | Derivado del glucósido C-arilo, método de preparación para el mismo y aplicaciones médicas de este |
| ES2605886T3 (es) | 2013-09-27 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Derivados de glucopiranosilo y sus usos en medicina |
| WO2015091313A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
| CN115282284A (zh) | 2014-01-23 | 2022-11-04 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
| EP3721882B1 (en) * | 2014-04-01 | 2024-08-28 | Boehringer Ingelheim Vetmedica GmbH | Treatment of pituitary pars intermedia dysfunction in equine animals |
| MX388192B (es) | 2014-09-25 | 2025-03-19 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de combinación y/o prevención de trastornos metabólicos en animales equinos. |
| CA2996458C (en) | 2015-08-27 | 2024-04-23 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising sglt-2 inhibitors |
| CN105294624B (zh) * | 2015-11-16 | 2018-01-12 | 山东罗欣药业集团股份有限公司 | 一种达格列净的制备方法 |
| CN108203432B (zh) * | 2016-12-20 | 2021-03-02 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
| AR111161A1 (es) | 2017-03-03 | 2019-06-12 | Novartis Ag | Régimen de dosificación para el inhibidor sglt1/2 (licogliflozin) |
| WO2020242253A1 (ko) * | 2019-05-30 | 2020-12-03 | 동아에스티 주식회사 | Sglt-2 억제제인 신규 엠파글리플로진 유도체 |
| CN113330017B (zh) * | 2019-12-19 | 2023-01-31 | 上海研健新药研发有限公司 | 一种SGLTs抑制剂的纯化方法及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| DK1213296T3 (da) | 1999-08-31 | 2004-08-16 | Kissei Pharmaceutical | Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
| EP1270584B1 (en) | 2000-03-17 | 2005-12-07 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| SK287811B6 (sk) | 2000-09-29 | 2011-10-04 | Kissei Pharmaceutical Co., Ltd | Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| KR101001848B1 (ko) | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물 |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| AR044399A1 (es) | 2003-05-20 | 2005-09-14 | Novartis Ag | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen |
| EA010655B1 (ru) | 2003-08-01 | 2008-10-30 | Янссен Фармацевтика Н.В. | Замещенные индазол-о-глюкозиды |
| ATE422204T1 (de) | 2003-08-26 | 2009-02-15 | Boehringer Ingelheim Int | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2005085237A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| ZA200606792B (en) | 2004-03-04 | 2007-12-27 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CA2574451A1 (en) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JP5086643B2 (ja) | 2004-11-18 | 2012-11-28 | キッセイ薬品工業株式会社 | １−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬 |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| CL2009000309A1 (es) * | 2008-02-13 | 2009-06-26 | Sanofi Aventis | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. |
| WO2010128152A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2012
- 2012-04-04 US US13/439,155 patent/US8614195B2/en not_active Expired - Fee Related
- 2012-04-12 JP JP2014504432A patent/JP5908973B2/ja not_active Expired - Fee Related
- 2012-04-12 EA EA201391525A patent/EA201391525A1/ru unknown
- 2012-04-12 MA MA36319A patent/MA35032B1/fr unknown
- 2012-04-12 WO PCT/IB2012/051799 patent/WO2012140597A1/en not_active Ceased
- 2012-04-12 MX MX2013011927A patent/MX2013011927A/es not_active Application Discontinuation
- 2012-04-12 PE PE2013002300A patent/PE20141039A1/es not_active Application Discontinuation
- 2012-04-12 UY UY0001034018A patent/UY34018A/es not_active Application Discontinuation
- 2012-04-12 BR BR112013026257A patent/BR112013026257A2/pt not_active IP Right Cessation
- 2012-04-12 PH PH1/2013/502140A patent/PH12013502140A1/en unknown
- 2012-04-12 EP EP12719083.3A patent/EP2697217B1/en active Active
- 2012-04-12 ES ES12719083.3T patent/ES2621007T3/es active Active
- 2012-04-12 CA CA2832958A patent/CA2832958A1/en not_active Abandoned
- 2012-04-12 KR KR1020137029813A patent/KR20140027250A/ko not_active Withdrawn
- 2012-04-12 AU AU2012241427A patent/AU2012241427B2/en not_active Ceased
- 2012-04-12 SG SG2013075908A patent/SG194463A1/en unknown
- 2012-04-12 AP AP2010307179A patent/AP2013007179A0/xx unknown
- 2012-04-12 CN CN201280028536.3A patent/CN103748090B/zh not_active Expired - Fee Related
- 2012-04-13 TW TW101113290A patent/TW201245219A/zh unknown
- 2012-04-13 AR ARP120101273A patent/AR086086A1/es unknown
- 2012-09-13 US US13/613,090 patent/US20130018005A1/en not_active Abandoned
-
2013
- 2013-10-07 IL IL228771A patent/IL228771A0/en unknown
- 2013-10-10 CO CO13241013A patent/CO6781541A2/es not_active Application Discontinuation
- 2013-10-11 TN TNP2013000413A patent/TN2013000413A1/fr unknown
- 2013-10-14 CU CU2013000139A patent/CU20130139A7/es unknown
- 2013-10-14 CR CR20130530A patent/CR20130530A/es unknown
- 2013-10-14 CL CL2013002973A patent/CL2013002973A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2697217B1 (en) | 2016-12-28 |
| BR112013026257A2 (pt) | 2019-09-24 |
| KR20140027250A (ko) | 2014-03-06 |
| US8614195B2 (en) | 2013-12-24 |
| US20120264700A1 (en) | 2012-10-18 |
| IL228771A0 (en) | 2013-12-31 |
| TW201245219A (en) | 2012-11-16 |
| MA35032B1 (fr) | 2014-04-03 |
| ES2621007T3 (es) | 2017-06-30 |
| AU2012241427A1 (en) | 2013-10-31 |
| AU2012241427B2 (en) | 2014-11-20 |
| UY34018A (es) | 2012-11-30 |
| MX2013011927A (es) | 2013-11-01 |
| CA2832958A1 (en) | 2012-10-18 |
| WO2012140597A1 (en) | 2012-10-18 |
| JP5908973B2 (ja) | 2016-04-26 |
| SG194463A1 (en) | 2013-12-30 |
| CN103748090A (zh) | 2014-04-23 |
| CR20130530A (es) | 2014-02-04 |
| CU20130139A7 (es) | 2014-01-29 |
| EA201391525A1 (ru) | 2014-02-28 |
| TN2013000413A1 (en) | 2015-03-30 |
| CN103748090B (zh) | 2016-09-14 |
| JP2014511874A (ja) | 2014-05-19 |
| PH12013502140A1 (en) | 2017-10-25 |
| AP2013007179A0 (en) | 2013-10-31 |
| CL2013002973A1 (es) | 2014-03-07 |
| PE20141039A1 (es) | 2014-08-30 |
| US20130018005A1 (en) | 2013-01-17 |
| CO6781541A2 (es) | 2013-10-31 |
| EP2697217A1 (en) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086086A1 (es) | Derivados glucosidos y usos de los mismos | |
| ES2657687T3 (es) | Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales | |
| AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
| EA201390723A1 (ru) | Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR072162A1 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR045261A1 (es) | Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores | |
| AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| UY38339A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas | |
| AR038843A1 (es) | Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| AR044116A1 (es) | Compuestos derivados de 5,7 diamino pirazolo [4,3-d] pirimidinas, intermediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la fabricacion de medicamentos. | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR081577A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |